Research programme: modified tetracyclines - Tetragenex

Drug Profile

Research programme: modified tetracyclines - Tetragenex

Alternative Names: INN 01137; INN 01147

Latest Information Update: 27 Apr 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tetragenex Pharmaceuticals
  • Class Tetracyclines
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Malignant melanoma; Prostate cancer

Most Recent Events

  • 31 Dec 2008 Preclinical trials in Bacterial infections in USA (unspecified route)
  • 31 Dec 2008 Preclinical trials in Malignant melanoma in USA (unspecified route)
  • 31 Dec 2008 Preclinical trials in Prostate cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top